What the F#@% is up with CBD: Part II
In the last blog we established some basic terminology for understanding this industry a little more clearly. Now, because CBD has risen so dramatically in popularity, we want to better understand what it is we know, what’s just gossip, and what to expect in the future.
Prior to the late 1990’s, CBD, cannabidiol, was thought to be inactive in the body. Then studies started coming out indicating that not only was it active, but it also demonstrated the potential for multiple pharmacological benefits. After a study in 2015 found a correlation between CBD intake and a reduced risk of colon cancer development in lab animals, every media outlet in the United States took up its usual task of reporting only pieces of information to millions of people.
So, what do we know for sure?
Unfortunately, we know quite a bit, but it’s not yet specifically tailored. This is a list of dozens of studies open to the public that have found tremendous benefits behind the use of CBD. However, the exact degree in which an individual might consume it, along with other potential cannabinoids and terpenoids, to help in aiding for a specific need is not yet fully understood. Independently, CBD does seem to have the potential to exude both anti-cancer and anti-inflammatory properties. And there truly is nothing about CBD that will produce the same psychoactive effects as THC.
We also know that while most CBD that has been made available in states where Cannabis is illegal is coming from industrial hemp. And we know that industrial hemp produces an extremely low amount of CBD, and is therefore extremely inefficient to use for CBD extraction.
What can we expect?
Until the recent passage of the 2018 Farm Bill, along with words from Dr. Scott Gottlieb, M.D. the commissioner of the FDA, CBD remained in a legally unclear space. While the Farm Bill specifically discusses hemp, and not CBD, clarification will be coming on how it will be permitted to research this compound as well as what language can be used for labeling, and claims related to diet or health, according to Dr. Gottlieb.
CBD still falls under the Controlled Substances Act because of its status as a cannabinoid, and it is within the purview of the DEA to enforce its sale and possession. However, with many CBD products in these states coming from industrial hemp and the prevailing majority of them not making any health claims; the DEA has not really been incentivized to pursue legal action.
So, with movement on the oversight and regulation of this promising compound quickly approaching, it’s going to be crucial to follow all the research, as well as the potentially misleading headlines, that continue to surface. For the next blog, we’ll look at some misleading ideas behind the uses of CBD, why they are misleading, and try to understand how we can all improve our ability to question what’s presented to us.